Sarah J Hyland

Sarah J Hyland

Auto-generated profile, based on publicly available information

Sarah J Hyland

Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2006 in BMC Genomics
Verified
Journal Article
Open access
PDF file
HÖHilal Özdağ
Hilal Özdağ
ATAndrew E Teschendorff
Andrew E Teschendorff
AAAhmed Ashour Ahmed
Ahmed Ashour Ahmed
SHSarah J Hyland
Sarah J Hyland
CBCherie Blenkiron
Cherie Blenkiron
CCCarlos Caldas
Carlos Caldas
Background: Post-translational modification of histones resulting in chromatin remodelling plays a key role in the regulation of gene expression. Here we report characteristic patterns of expression of 12 members of 3 classes of chromatin modifier genes in 6 different cancer types: histone acetyltransferases (HATs)-EP300, CREBBP, andPCAF; histone deacetylases (HDACs)-HDAC1, HDAC2, HDAC4, HDAC5, HDAC7A, andSIRT1; and histone methyltransferases (HMTs)-SUV39H1andSUV39H2. Expression of each gene in 225 samples (135 primary tumours, 47 cancer cell lines, and 43 normal tissues) was analysedby QRT-PCR, normalized with 8 housekeeping genes, and given as a ratio by comparison with a universal reference RNA.Results: This involved a total of 13,000 PCR assays allowing for rigorous analysis by fitting a linear regression model to the data. Mutation analysis ofHDAC1, HDAC2, SUV39H1, andSUV39H2revealed only two out of 181 cancer samples (both cell lines) with significant coding-sequence alterations. Supervised analysis and Independent Component Analysis showed that expression of many of these genes was able to discriminate tumour samples from their normal counterparts. Clustering based on the normalized expression ratios of the 12 genes also showed that most samples were grouped according to tissue type. Using a linear discriminant classifier and internal cross-validation revealed that with as few as 5 of the 12 genes,SIRT1, CREBBP, HDAC7A, HDAC5andPCAF, most samples were correctly assigned.Conclusion: The expression patterns of HATs, HDACs, and HMTs suggest these genes are important in neoplastic transformation and have characteristic patterns of expression depending on tissue of origin, with implications for potential clinical application.

31 August 2007 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MKMichael Krypuy
Michael Krypuy
AAAhmed Ashour Ahmed
Ahmed Ashour Ahmed
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
SHSarah J Hyland
Sarah J Hyland
AGAustralian Ovarian Cancer Study Group
Australian Ovarian Cancer Study Group
ADAlexander Dobrovic
Alexander Dobrovic
Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples. Methods: We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status. Results: One cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the predicted exons. Conclusion: HRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the amount of sequencing required in mutational studies of TP53.